Summary Basis for Regulatory Action

First Page		Document Content
Haemophilia Coagulation system Viruses CSL Behring Virology Transfusion medicine Factor XIII deficiency Factor X Behring Biology Medicine Blood		Summary Basis for Regulatory Action Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 185,12 KB Share Document on Facebook

	CSL Behring AG WankdorfstrasseBern 22 Switzerland sitem-insel AG DocID: 1uREs - View Document
	News Releases Global Home \| CSL Behring US \| CSL Plasma \| All CSL Behring Web Sites DocID: 1sx8q - View Document
	Uwe E. Jocham Direktionspräsident CSL Behring Recombinant Facility AG, Lengnau/Schweiz Uwe E. Jocham, geboren in Frankfurt, Deutschland, studierte Pharmazie an der LudwigMaximilians-Universität (LMU) in München. Nach DocID: 1sesH - View Document
	MAJOR THERAPEUTIC PRODUCTS MARKETED by CSL Behring Hematology Specialty Care DocID: 1sb17 - View Document
	[Product Monograph Template - Schedule D] DocID: 1rjWd - View Document